Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

71 results about "Amyloid beta" patented technology

Amyloid beta (Aβ or Abeta) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of the amyloid plaques found in the brains of people with Alzheimer's disease. The peptides derive from the amyloid precursor protein (APP), which is cleaved by beta secretase and gamma secretase to yield Aβ. Aβ molecules can aggregate to form flexible soluble oligomers which may exist in several forms. It is now believed that certain misfolded oligomers (known as "seeds") can induce other Aβ molecules to also take the misfolded oligomeric form, leading to a chain reaction akin to a prion infection. The oligomers are toxic to nerve cells. The other protein implicated in Alzheimer's disease, tau protein, also forms such prion-like misfolded oligomers, and there is some evidence that misfolded Aβ can induce tau to misfold.

Extracellular vesicle drug delivery system, preparation method thereof and application of extracellular vesicle drug delivery system in treatment of Alzheimer's disease

PendingCN121825870AOrganic active ingredientsCell dissociation methodsAmyloid betaMicroglial cell activation
The invention belongs to the technical field of biological medicine, and particularly relates to an extracellular vesicle drug delivery system, a preparation method thereof and application of the extracellular vesicle drug delivery system in treatment of Alzheimer's disease. According to the invention, one or more of stilbene glucoside, emodin, kaempferol, resveratrol and quercetin are used for regulating and controlling the expression of miRNA (micro Ribonucleic Acid) related to the disease progress in the extracellular vesicles, and the result shows that one or more of miR-let-7c-5p, miR-486-5p, miR-132-3p, miR-160b and miR-129-5p is remarkably up-regulated, and one or more of miR-342-3p, miR-16-5p and miR-125b-5p is remarkably down-regulated. The regulated extracellular vesicles can be used for treating Alzheimer's disease, relieving Tau protein abnormal phosphorylation, reducing amyloid protein beta deposition, inhibiting microglial cell activation, protecting neuronal cells and relieving memory deficits.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES

CRISPR / Cas12a-based electrochemical biosensor as well as preparation method, test method and application thereof

The invention relates to the technical field of electrochemical analysis and detection, in particular to an electrochemical biosensor based on CRISPR / Cas12a as well as a preparation method, a detection method and application of the electrochemical biosensor. An electrochemical biosensor based on CRISPR / Cas12a comprises a Cas12a-crRNA detection system, an APT-ActDNA adaptation system and an electrochemical aptamer sensor, and when a target analyte exists, the Cas12a-crRNA detection system and the APT-ActDNA adaptation system are matched with each other to react with the target analyte, so that the electrochemical aptamer sensor generates an electrochemical signal. According to the technical scheme, the problems of specific recognition and detection of amyloid beta peptide (Abeta) in a complex biological sample are solved, the preparation method is simple, the cost is low, and the detection method is high in sensitivity and accuracy.
Owner:ANHUI UNIV

Monoclonal antibody against amyloid beta, and method for measuring amyloid beta-related peptide using said antibody

The present invention provides a novel anti-Aβ antibody capable of detecting an Aβ related peptide, a method for measuring an Aβ related peptide in a biological sample by immunochemically using the above-mentioned novel anti-Aβ antibody, and a kit. A monoclonal antibody that recognizes an Aβ related peptide, and is produced by a hybridoma deposited under the accession number NITE BP-02998 at the NITE Patent Microorganisms Depositary of the National Institute of Technology and Evaluation. An antibody-immobilized carrier that includes a carrier and the monoclonal antibody defined in claim 1 bound to the carrier. A kit for measuring an Aβ related peptide, comprising the antibody-immobilized carrier.
Owner:SHIMADZU CORP

Compounds, systems, and techniques for removal of peripheral amyloid beta peptide with albumin binding competitors

Compounds, systems, kits, methods, and / or apparatuses may be operative to reduce amyloid beta (Aβ) peptide in a patient, including a central nervous system (CNS) of the patient and / or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a Aβ displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds Aβ (for instance, Aβ peptide or non-plaque Aβ) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free Aβ peptide (for instance, Aβ monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and / or artificial processes, such as dialysis. Increased removal of the free Aβ peptide in the periphery may ultimately lead to less Aβ peptide in the CNS, which may decrease Aβ plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.
Owner:FRESENIUS MEDICAL CARE HOLDINGS INC

Use of methylated peptide as therapeutic agent for degenerative brain diseases

The present invention relates to a use of a methylated peptide as a therapeutic agent for degenerative brain diseases. Specifically, it has been confirmed that the methylated peptide according to the present invention exhibits improved solubility, bioavailability, phagocytosis by microglia, and anti-inflammatory efficacy compared to a conventional unmodified peptide, and exhibits excellent amyloid beta reduction efficacy compared to a conventional unmodified peptide in an animal model of degenerative brain diseases. Therefore, the methylated peptide according to the present invention can be usefully used as an active ingredient of a composition for preventing or treating degenerative brain diseases and cognitive impairment, learning disability, or memory impairment associated therewith.
Owner:KINE SCI CO LTD

Anti-amyloid beta fibril / oligomer antibodies and uses thereof

The present disclosure provides anti-amyloid [beta] (A [beta]) antibodies and antibody fragments that preferentially bind to soluble amyloid [beta] fibrils / oligomers and trigger ADPC in microglial cells; anti-amyloid [beta] (A [beta]) antibodies and antibody fragments that reduce soluble amyloid [beta] fibril / oligomer levels and insoluble amyloid [beta] plaques in brain tissue; and the use of anti-A [beta] fibril / oligomer antibodies and antibody fragments in the treatment, prevention, diagnosis, screening and monitoring of conditions associated with A [beta] protein aggregation, in particular Alzheimer's Disease (AD).
Owner:MABWELL THERAPEUTICS INC

Application of Yangxue oral liquid in preparing neuroprotective drugs for Alzheimer's disease and / or Parkinson's disease

ActiveCN118217332BHeavy metal active ingredientsNervous disorderAmyloid betaNeuroprotective Drugs
The present invention provides the use of Yangxue Oral Liquid in the preparation of drugs for neuroprotection against Alzheimer's disease and / or Parkinson's disease, and belongs to the field of biopharmaceutical technology. The present invention provides the use of Yangxue Oral Liquid in the preparation of drugs for neuroprotection against Alzheimer's disease and / or Parkinson's disease. By verifying the effects of Yangxue Oral Liquid on the amyloid beta-induced neuronal apoptosis model, the cobalt chloride-induced SH‑SY5Y cell hypoxia model, and the LPS-induced SH‑SY5Y cell inflammation model, the results showed that Yangxue Oral Liquid has a neuroprotective effect against Alzheimer's disease and / or Parkinson's disease. Therefore, the application provided by the present invention provides a new means for neuroprotection against Alzheimer's disease and / or Parkinson's disease.
Owner:HUBEI FENGHUANG BAIYUNSHAN PHARM CO LTD

Novel molecule for diagnosis

To provide a novel amyloid beta (A beta) binding molecule, especially an amyloid beta antibody or an antigen-binding fragment thereof, and / or use of them.SOLUTION: There is provided an amyloid beta binding antibody including: VH-CDR1 including a specific amino acid sequence, VH-CDR2 including a specific amino acid sequence, VH-CDR3 including a specific amino acid sequence, VL-CDR1 including a specific amino acid sequence, VL-CDR2 including a specific amino acid sequence, and VL-CDR3 including a specific amino acid sequence; or an antigen-binding fragment thereof. In one embodiment, independently of an amyloid beta peptide or a three-dimensional structure states of a seed, an amyloid beta binding antibody or an antigen binding fragment thereof selectively binds to an amyloid beta peptide or seed in a solution, or captures the amyloid beta peptide or seed.SELECTED DRAWING: None
Owner:AC IMMUNE SA

Catalytic antibodies and methods of use thereof

The present application provides methods, compositions and kits for determining SHD-catalyzed antibody levels in a biological sample and for treating or preventing protein aggregation disease (PAD) in an individual. Catalytic antibodies that specifically recognize amyloid beta (A beta) peptides and methods of using the same are also provided.
Owner:AB STUDIO INC

Composition for predicting clinical stage of alzheimer's disease and kit using the same

The composition for predicting Alzheimer's disease prognosis comprising a detection reagent that specifically binds to any one or more genes selected from the group consisting of Nos1 (Nitric oxide synthase 1), Aph1B (Anterior pharynx defective 1 homolog B), Ryr3 (Ryanodine receptor 3), Atf6 (Activating transcriptional factor 6), Ip3r (Inositol trisphosphate receptor), Nep (Neprilysin), Cdk5 (cyclin dependent kinase 5) and Abad (Amyloid beta-binding alcohol dehydrogenase), a kit, and a method for providing information on Alzheimer's disease prognosis of the present invention can rapidly and accurately predict the prognosis of Alzheimer's disease, and can determine the prognosis for a drug by comparing the expression level before and after drug administration, so that an appropriate treatment direction can be determined according to the predicted prognosis. Therefore, they have an effect that can greatly contribute to the reduction of mortality due to Alzheimer's disease.
Owner:INDUSTRYACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY

A combination of scyllo-inositol and n-acetyl cysteine and related compounds

The invention relates to the use of scyllo-inositol alone or in combination with other active ingredients including the compound N-acetylcysteine or a derivative thereof to support cognitive health in a subject that takes the product or combination product. The compositions, which are inclusive of oral dosage forms such as tablets or capsules, are provided to the subject which is inclusive of humans or other mammals such as dogs or cats or other animals in need of cognitive improvement. The combination product(s) break up amyloid beta aggregates and promote the clearance of amyloid beta fibrils from the glymphatic system as well as the treatment of disease and conditions that are acerbated by free radicals.
Owner:EIRGEN PHARMA LTD

ANTIBODIES BINDING TO A BETA pE3

An antibody or antigen-binding fragment thereof that binds to A [beta] pE3, i.e., to the N-terminal truncated and pyroglutamic acid modified form of amyloid [beta] (A [beta]), and therapeutic and diagnostic uses thereof are disclosed.
Owner:BIOSCOPE

Intracellular domain of AXL or fragment derived therefrom, and use for regulating autophagy using same

The present invention relates to an intracellular domain of AXL or a fragment derived therefrom, and a use for regulating autophagy using same, wherein the intracellular domain of AXL or the fragment derived therefrom can regulate a selective autophagy pathway in response to an intracellular amyloid beta signal.
Owner:INST FOR BASIC SCI

Pharmaceutical composition containing neprilysin-overexpressing stem cell, conditioned medium thereof, and exosome isolated therefrom as active ingredient for prevention or treatment of cognitive impairment

Disclosed herein is a pharmaceutical composition containing a neprilysin-overexpressing stem cell, a conditioned medium thereof, and an exosome isolated therefrom as an active ingredient for prevention or treatment of cognitive impairment. Having the functions of protecting nerve cells, inhibiting the accumulation of amyloid beta, known as a cause of cognitive impairment-related disease in animal models, increasing an expression level of acetyl choline, and improving cognitive functions in animal models, the neprilysin-overexpressing stem cells, the conditioned medium thereof, or the exosomes isolated therefrom according to the present disclosure can find advantageous applications in treating cognitive impairment.
Owner:DESIGNED CELLS CO LTD

Animal model for rapid attack of Alzheimer's disease amyloid beta plaque lesion

PendingCN121263062ACompounds screening/testingVectorsAmyloid betaAmyloid precursor protein
Provided herein are compositions comprising a nucleic acid encoding an amyloid-beta precursor protein and / or a nucleic acid encoding premature protein-1, cells comprising these compositions, animals comprising these compositions, methods of making these cells and animals, methods of modeling Alzheimer's disease, and methods of preparing such cells and animals. A method of assessing a treatment candidate for treating or ameliorating a symptom or phenotype of Alzheimer's disease, and a method of assessing a treatment candidate for preventing or preventing a symptom or phenotype of Alzheimer's disease.
Owner:REGENERON PHARMACEUTICALS INC

Use of lecanemab in ophthalmological conditions

This disclosure related to a method of preventing or treating an amyloid- associated retinal disease in an individual in need thereof, the method comprises administering to the individual a therapeutically effective amount of an antibody with high affinity and specificity for amyloid beta (Abeta) oligomers, Abeta protofibrils or combination thereof.
Owner:GALIMEDIX THERAPEUTICS INC

Antibody that binds to AβpE3

Disclosed are antibodies or antigen-binding fragments thereof that bind to AβpE3, an N-terminally truncated, pyroglutamic acid-modified form of amyloid beta (Aβ), and their therapeutic and diagnostic uses.
Owner:BIOARCTIC AB

Neutralizing anti-amyloid beta antibodies for the treatment of Alzheimer's disease

Binding polypeptides (e.g., antibodies and antigen-binding fragments thereof) that specifically bind one or more species of soluble, AD brain-derived synaptotoxic amyloid beta (Aβ) without binding to classical monomeric, protofibrillar or fibrillar Aβ, are provided. Pharmaceutical compositions comprising binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of making binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of treating Alzheimer's disease using binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided. Methods of reducing one or more symptoms of Alzheimer's disease using binding polypeptides that specifically bind one or more species of soluble, synaptotoxic Aβ are provided.
Owner:SANOFI SA(FR) +1

Method for diagnosing early and classifying stages of alzheimer's disease and determining amyloid beta accumulation in brain by using tau protein-derived phosphorylated peptide

A method for early diagnosis or stage classification of Alzheimer's disease includes obtaining a tau protein-derived phosphorylated peptide from an isolated biological sample and quantifying the tau protein-derived phosphorylated peptide. Through the quantification of tau protein-derived phosphorylated peptides, it is possible to effectively diagnose Alzheimer's disease at an early stage or classify its stages, and determine the accumulation of amyloid beta in the brain.
Owner:GWANGJU INST OF SCI & TECH +2

Anti-amyloid beta antibodies and uses thereof

PCT designated stageWO2026178324A1Antiendomysial antibodiesAmyloid beta
The present application provides anti-Aβ constructs (e.g., anti-Aβ antibodies) that bind to Aβ (e.g., Aβ40 and Aβ42), nucleic acid molecules encoding an amino acid sequence of the anti-Aβ constructs, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-Aβ constructs, pharmaceutical compositions containing the anti-Aβ constructs, and methods of using the anti-Aβ constructs or compositions.
Owner:DYNAMICURE BIOTECHNOLOGY LLC

Polynucleotides encoding APOA-1 fusion polypeptides

ActiveUS12509501B2Antibacterial agentsNervous disorderDimerSterol ester
Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin / kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.
Owner:THERIPION INC

Pharmaceutical composition for preventing or treating neurodegenerative diseases comprising aconogonon alpinum extract, fraction thereof, or compound isolated therefrom

The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases, comprising an Aconogonon alpinum extract, a fraction thereof, or a compound of Chemical Formula 1 isolated therefrom and, more specifically, to a pharmaceutical composition comprising an Aconogonon alpinum extract, a fraction thereof, or a compound of Chemical Formula 1 isolated therefrom to activate autophagy and inhibit the production of amyloid beta, thereby exhibiting a prophylactic or therapeutic effect against neurodegenerative diseases.
Owner:IND ACAD COOP GRP OF SEJONG UNIV

In vitro diagnostic method of neurodegenerative disease

The present invention relates to a method for the in vitro diagnosis of a neurodegenerative disease in a human or animal individual in the early stage, comprising a step comprising the detection of the presence of at least one marker selected from the group consisting of derived forms of amyloid beta (A beta) peptides, the derivative forms are selected from oligomers of the peptide and pre-fibrotic and fibrotic aggregated forms of the peptide, and derivative forms of a phosphorylated tau protein, and the derivative forms are selected from over-phosphorylated forms of the protein, aggregated forms of the protein and modified phosphorylated tau proteins resulting from one or more post-translational modifications; the presence of a marker is detected in a fecal sample of the individual.
Owner:UNIVERSITE GRENOBLE ALPES +1

Anti-amyloid beta fibril / oligomer antibodies and uses thereof

The present disclosure provides anti-amyloid beta (Aβ) antibodies and antibody fragments that preferentially bind to soluble amyloid Aβ fibrils / oligomers and trigger ADPCs in microglia; anti-amyloid beta (Aβ) antibodies and antibody fragments that reduce soluble amyloid Aβ fibril / oligomer levels and insoluble amyloid Aβ plaques in brain tissue; and uses of anti-Aβ fibril / oligomer antibodies and antibody fragments in the treatment, prevention, diagnosis, screening and monitoring of conditions associated with Aβ protein aggregation, in particular Alzheimer's disease (AD).
Owner:MABWELL THERAPEUTICS INC

Methods of treating alzheimer's disease

PCT designated stageWO2026064441A1Nervous disorderImmunoglobulins against animals/humansImmuno assayAmyloid beta
The disclosure is related to methods of treating a subject with Alzheimer's Disease (AD) using anti-amyloid beta (Aβ) therapy. The patient may be treated based on the measurement and analysis of biomarker levels, such as plasma Aβ42 / 40 ratio, pTau181 and pTau217. The disclosure includes a systematic approach called CP Convert for converting biomarker measurements across different analytical platforms, enabling comparison of pTau217 data from LC-MS / MS, SIMOA, and chemiluminescent enzyme immunoassay platforms. Methods demonstrate that pTau217 has superior diagnostic accuracy compared to Aβ42 / 40 ratio and pTau181 for detecting brain amyloid positivity. Implementation of pTau217 prescreening can significantly reduce Aβ-PET testing, decreasing patient burden and clinical trial costs. The CP Convert methodology can be validated using independent cohorts, demonstrating robust cross-platform conversion for research applications.
Owner:OTHAIR PROTHENA LTD +3